K. Jiang

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

A. Jakubowiak, J. Zonder, T. Karrison, 2022, JAMA oncology.

A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma

A. Jakubowiak, A. Chari, J. Zonder, 2023, European journal of haematology.

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

A. Jakubowiak, A. Stefka, B. Derman, 2021, Blood Cancer Journal.

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.

A. Jakubowiak, A. Stefka, B. Derman, 2020 .